People taking GLP-1 weight loss drugs may not be consuming enough protein, study finds

People taking GLP-1 receptor agonists for weight loss are at risk of not consuming enough protein, with most falling below recommended protein targets, according to new real-world research being presented at the European Congress on Obesity (ECO 2026, Istanbul, 12–15 May).

The study, led by Dr Rebecca De Lorenzo and Professor Patrizia Rovere Querini at IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University in Milan, Italy, in collaboration with the Robin Health team, used an AI-powered dietary tracking app and found that 88% of GLP-1 users didn’t meet national protein guidelines and were more likely to skip meals, reducing opportunities for adequate protein intake across the day.

“While GLP-1 RAs produce impressive weight loss, the question of whether meaningful muscle loss accompanies fat loss with these therapies is still hotly debated,” says lead author Dr Valentina Vinelli.

“What remains universally agreed, however, is that protecting muscle mass should be a central goal of any weight-loss programme.

“Muscle health depends on sufficient protein intake and regular physical activity, especially resistance exercise.

“For people using GLP-1 RAs, reduced appetite can make it harder to meet protein needs, making what you eat matter more than ever, especially given that protein requirements tend to be higher in people with obesity and during active weight loss.

“Protein requirements should always be personalised, expressed as grams per kilogram of adjusted body weight, rather than treated as a one-size-fits-all target.”

Dr Vinelli continued.

“While GLP-1 RAs medications are transforming obesity care, we still know very little about how they affect eating patterns and nutrient intake.

“What’s more, many people taking GLP-1 RAs receive little or no systematic guidance on diet quality, protein intake, or micronutrient adequacy,” she says.

The study

Researchers analysed 5741 days of data from 332 adults with overweight or obesity (who provided consent) using a mobile dietary-tracking app between July 2025 and February 2026.

They compared total energy intake, macronutrient intake, weight-adjusted protein adequacy, meal patterns, and weight loss between 116 GLP-1 RAs users (using either semaglutide or tirzepatide) and 216 non-users (average BMI 31.3 vs 30.6 kg/m², 52.5 vs 50.0 years, 72% vs 63% female, respectively).

Of the 116 GLP-1 RA users in the study, 87 logged at least one injection in the app.

Of those, 62 were using tirzepatide, and 25 were using semaglutide.

The remaining 29 were identified as GLP-1 users through their profiles, but did not log individual injections.

The researchers note that it’s “important to note that the dose data reflects what users chose to log in the app.”

Of the 25 semaglutide users who logged their injections, 10 (40%) recorded a maximum dose of 0.25 mg (the starting dose), 4 (16%) recorded 0.5 mg, 6 (24%) recorded 1.0 mg, 2 (8%) recorded 1.7 mg, and 3 (12%) recorded 2.4 mg (the maintenance dose).

Of the 62 tirzepatide users who logged their injections, 12 (19%) recorded a maximum dose of 2.5 mg (the starting dose), 21 (34%) recorded 5.0 mg, 10 (16%) recorded 7.5 mg, 17 (27%) recorded 10.0 mg, and 2 (3%) recorded 12.5 mg.

The analysis found that participants using GLP-1 RAs medications reported significantly lower total energy intake compared with non-users (average 1,102 vs 1,281 kcal/day) as well as significantly lower intake of macronutrients, including protein (53.8 vs 62.0 g/day), carbohydrates (128 vs 143 g/day), and fat (39.7 vs 45.7 g/day).

Despite lower absolute intake, macronutrient distribution (the proportion of daily calories derived from macronutrients) was nearly identical (protein 20% vs 19%; carbohydrate 47% vs 46%; fat 33% vs 34%), indicating a proportional reduction in food intake rather than changes in diet quality.

However, weight-adjusted daily protein intake was critically low in GLP-1 RAs users (0.6 g/kg/day), with the majority (88%) falling below the Italian national recommendation for protein intake (of 0.9 g/kg/day).

In non-users, protein consumption was also below this recommendation at 0.7 g/kg/day, with 69% below the national recommendation, indicating that inadequate protein consumption is a concern regardless of the weight-loss strategy employed, but more so among those using GLP-1-RAs.

Moreover, GLP-1 RAs users were much more likely to skip breakfast (31% vs 16% of days), lunch (31% vs 18%), and dinner (40% vs 30%) than non-users — thereby reducing opportunities for adequate protein distribution across the day.

As expected, among the subset of 177 participants (76 GLP-1 RAs users and 101 non-users) with longitudinal weight data, GLP-1 RAs users experienced significantly greater weight loss than non-users (average −2.2 kg, −2.5% vs −0.2 kg, −0.2%), with nearly a quarter (24%,18 participants) achieving clinically meaningful weight loss (at least 5% body weight loss) compared with just 3% (3 participants) of non-users.

The authors explain that the modest weight loss seen in the GLP-1 group reflects the real-world conditions of the study.

They say that the study did not “independently verify or control drug adherence; medication use was self-reported through the app, and it is possible that some users continued taking their medication without logging it”.

The researchers explain that “most users tracked their weight for only a few weeks (median duration between first and last weight measurements across the group was 22 days), and the majority of those who did log their injections appeared to still be in the dose-titration phase rather than on full maintenance doses”.

“However, among the 13 users who tracked weight for at least 3 months, the average weight lost was 7.3%, on course towards the 10% plus weight loss seen at 12 months in randomised clinical trials,” they say.

Need ‘proactive monitoring’ and ‘personalised guidance’

“Real-world GLP-1 RA use in adults with overweight or obesity is associated with widespread protein inadequacy and increased meal skipping, underscoring the urgent need for proactive nutritional monitoring and personalised dietary guidance to be integrated alongside obesity treatment to support long-term health beyond weight loss,” says Dr Vinelli.

“In our future work, we will look beyond protein to explore how GLP-1 RAs affect the intake of other key nutrients and examine how real-time mobile apps could help people stay on track with healthy eating and lifestyle habits throughout their journey.”

Study limitations

The authors acknowledge several limitations to the study, including the small sample size and its descriptive nature, which preclude causal inference and warrant confirmation in larger studies.

In addition, dietary data were self-reported via app-based logging and may underestimate true intake, although AI-assisted multimodal capture likely reduces recall bias compared to traditional dietary assessment methods.

Must Read